Company intelligence / Profile preview
Auro Vaccines
- Ownership
- Private
- Development stage
- Phase 1
Overview
Auro Vaccines is a clinical-stage vaccine developer using proprietary PBS Vax™ and VesiculoVax™ platforms to create both preventive and therapeutic vaccines. Their technology enables tailored immune responses for high unmet medical needs in infectious diseases and cancer. Early clinical trials have demonstrated safety, immunogenicity, and single-dose protection in animal models against viruses like Ebola and Marburg. Most pipeline programs are preclinical or pending further development[3][4][6].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Therapeutic vaccinesProphylactic vaccinesDNA vaccinesViral vector vaccines (VesiculoVax™, attenuated VSV, Isfahan viral vectors)
- Industry
- Biotech
Drug pipeline
18 assets17 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Auro Vaccines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Auro Vaccines.